Background: Collecting duct carcinoma of the kidney (CDC) is a rare cancer associated with bad prognosis and, at present, with no specific effective therapies.
Case Report: We report a clinical case with disseminated highgrade CDC presenting with widespread metastasis to both lungs, pelvic bones, axial skeleton, and the central nervous system (posterior fossa, both hemispheres and pituitary-hypothalamic). The primary tumor in the kidney was demonstrated (by fluorescence in situ hybridization and immunohistochemistry with Herceptest (3+ score)) to significantly overexpress HER2. Critically ill at presentation, the patient received oral capecitabine together with double HER2 blockade with both intravenous trastuzumab and oral lapatinib. His clinical response was a dramatic improvement and a progressive decline in the radiological size of all of his multiple cancer lesions.
Conclusion: Double HER2 blockade is an effective therapy in disseminated CDC even in the presence of brain metastases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000345041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Production and functional analysis of a phage displayed scFv recombinant antibody targeting EGFR/HER2 dimerization domain.
Protein Expr Purif
December 2024
Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; Molecular and Cell Biology Research Center (MCBRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address:
Background: Tumor cells exploit epidermal growth factor receptor (EGFR) family to develop resistance against therapeutic antibodies, such as Herceptin. Upon ligand binding, dimerization between EGFR and HER2 is one of the most important causes of treatment failure in breast cancer and other cancers expressing EGFR and HER2. The aim of this study was to develop and evaluate the function of a human recombinant single-chain variable fragment (scFv) antibody against the dimerization domain of EGFR to inhibit its interaction with other members of the epidermal growth factor receptor family, especially HER2.
View Article and Find Full Text PDFEfficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.
Cancer Treat Rev
January 2025
SOLTI Cancer Research Group, Barcelona, Spain; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:
Article Synopsis
- Antibody-drug conjugates (ADCs) T-DXd and SG improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy in metastatic breast cancer (MBC) but have not been directly compared.
- A network meta-analysis revealed that T-DXd and SG had similar efficacy in hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low MBC, while T-DXd showed better results against standard chemotherapy.
- T-DXd demonstrated more favorable outcomes in HR+/HER2-low for both PFS and OS, but SG showed higher rates of specific side effects, including neutropenia and diarrhea, while T-DXd was associated with more serious adverse events like pneumonitis and cardiotoxicity
Negative response to immunotherapy in dMMR or MSI-H gastric cancer with APC and PTEN mutations: a case report.
Front Oncol
November 2024
Department of Oncology, The Affiliated Xinghua People's Hospital, Medical School of Yangzhou University, Xinghua, Jiangsu, China.
Background: Microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) represents a distinct molecular phenotype observed in malignant tumors. These tumors typically exhibit high levels of programmed cell death 1 ligand 1 (PD-L1) expression and high tumor mutational burden (TMB), resulting in an enhanced response to immune checkpoint inhibitors (ICI) therapy. The emergence of ICI has transformed the therapeutic strategy of gastric cancer (GC).
View Article and Find Full Text PDFA surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report.
Front Immunol
December 2024
Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
The outcome of patients with recurrent/metastatic cervical cancer (R/M CC) is poor, with a 5-year survival rate of only 10%-20%. Recent advances in immunotherapy renewed its interest in R/M CC treatment. It has been suggested that cadonilimab, a novel bispecific antibody targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), significantly improved the survival outcomes of the R/M CC.
View Article and Find Full Text PDFAdjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study.
Clin Breast Cancer
November 2024
Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Institute for Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:
Background: For patients who achieve pathologic complete response (pCR) after neoadjuvant chemotherapy with trastuzumab (T) and pertuzumab (P), the benefit of adding P to T remains uncertain. We compared survival outcomes according to the type of adjuvant anti-HER2 therapy in patients with pCR after chemotherapy with TP.
Method: Patients who achieved pCR in both the breast and axilla after neoadjuvant chemotherapy with TP were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!